This is a combination of two drugs already on the market phentermine and topiramate. WebMD, and Wikipedia, while not adequate for a scientific paper, usually are pretty good for background. I would have to say I do not know of students who have been on this. I always advise those who want to loose significant weight to talk to their doctor, and to a nutritionist, in addition to any physical activity they and their doctor feel comfortable they start with.
I applaud you for wanting to educate yourself about what your clients may be taking. While it is never appropriate to recommend any medication or medical treatment without a medical degree, it is so helpful for us as professionals to understand the potential side effects of medications they may be on as they may effect their exercise program.
I am attaching some info you might find helpful:
Last Updated: October 01, 2012
As an adjunct to a reduced┬¡calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of ÔëÑ30kg/m2 or ÔëÑ27kg/m2 in the presence of at least one weight related co┬¡morbidity (eg, hypertension, type 2 diabetes, or dyslipidemia).
The effect of phentermine on chronic weight management is likely mediated by release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The effect of topiramate may be due to its effects on both appetite suppression and satiety enhancement, induced by a combination of pharmacologic effects including augmenting the activity of the neurotransmitter gamma┬¡aminobutyrate, modulation of voltage┬¡gated ion channels, inhibition of AMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.
The effect of Qsymia was studied in two trials in obese patients (Study 1) and in obese and overweight patients with two or more significant co┬¡morbidities (Study 2). After 1 year of Qsymia treatment, all dose levels resulted in statistically significant weight loss compared to placebo. A statistically significant greater proportion of the patients randomized to Qsymia than placebo achieved 5% and 10% weight loss.
Sympathomimetic amine + antiepileptic.
Phentermine HCl/topiramate extended┬¡release; 3.75mg/23mg, 7.5mg/4
6mg, 11.25mg/69mg, 15mg/92mg; caps.
Take once daily in the AM. Initially 3.75mg/23mg for 14 days; then increase to 7.5mg/46mg and evaluate weight loss after 12 weeks on this dose. If patient has not lost ÔëÑ3% baseline body weight, discontinue or escalate dose. To escalate dose: increase to 11.25mg/69mg for 14 days, then increase to 15mg/92mg and evaluate weight loss after additional 12 weeks at this dose. If patient has not lost ÔëÑ5% baseline body weight, discontinue by taking a dose every other day for at least 1 week prior to stopping altogether. Qsymia 3.75mg/23mg and 11.25mg/69mg strengths are for titration purposes only. Renal (moderate or severe), hepatic (moderate) impairment: max 7.5mg/46mg once daily.